Tom Dreisbach
Tom Dreisbach is a correspondent on NPR's Investigations team focusing on breaking news stories.
His reporting on issues like COVID-19 scams and immigration detention has sparked federal investigations and has been cited by members of congress. Earlier, Dreisbach was a producer and editor for NPR's Embedded, where his work examined how opioids helped cause an HIV outbreak in Indiana, the role of video evidence in police shootings and the controversial development of Donald Trump's Southern California golf club. In 2018, he was awarded a national Edward R. Murrow Award from RTDNA. Prior to Embedded, Dreisbach was an editor for All Things Considered, NPR's flagship afternoon news show.
-
New York Gov. Andrew Cuomo allegedly relied on liberal allies to fight charges of sexual harassment. Now, one of those allies, the head of Human Rights Campaign, is facing demands that he resign. -
Some extremists weaponize irony and absurdity as a method for recruiting new members and avoiding criticism. Such tactics can mask the danger that extremists pose, experts say. -
The conspiracy theorist Alex Jones sells dietary supplements through Amazon despite being banned from other platforms. Amazon receives a cut of the profits. -
An NPR review of federal charges against people involved in the Jan. 6 U.S. Capitol riot shows they were armed with a wide variety of weapons, contradicting a false claim that rioters were not armed. -
Many Fox News hosts, commentators and guests helped stoke the pro-Trump protests that became an assault on Congress. Among those influenced was Ashli Babbitt, who died while storming the Capitol. -
Co-Diagnostics, a company that has provided coronavirus tests to three state governments, has come under intense scrutiny for claims about its tests' accuracy and stock sales by company leaders.
-
The Federal Trade Commission issued warning letters to several companies that marketed an unproven drug to treat COVID-19. Sales of the nonapproved drug, thymosin alpha-1, were first reported by NPR. -
Pfizer's CEO sold $5.6 million worth of stock on Monday. The company says the stock sale was made as part of a preset plan. But NPR found irregularities about when the CEO entered into that plan.
-
An NPR investigation has identified a web of more than 30 medical practices and compounding pharmacies in over a dozen states that have made claims about thymosin alpha-1 online and on social media. -
Moderna is currently developing a promising, yet still unproven, vaccine against the coronavirus. But Moderna executives have already sold tens of millions of dollars worth of stock in the company.
